Fgfr1 - Fibroblast growth factor receptor 1 Gene

中文名称：成纤维细胞生长因子受体 1

种属: Rattus norvegicus

同用名: MFR; c-fgr; FGFR-1; bFGF-R; bFGF-R-1

基因 ID: 79114 | 基因类型: protein coding

关于 Fgfr1

Primary_assembly 16: 66,494,042-66,547,350 reverse strand.mRatBN7.2:CM026989.1

This gene has 2 transcripts (splice variants), 292 orthologues, 54 paralogues and is associated with 87 phenotypes. Biased expression in Kidney (RPKM 185.8), Lung (RPKM 166.8) and 9 other tissues.

功能概要

使细胞粘附分子结合活性和信号受体结合活性。参与多个过程，包括细胞对组胺的反应；神经元发育；和细胞群增殖的正调节。位于细胞核；细胞质的核周区；和质膜。用于研究肺动脉高压。多种疾病的生物标志物，包括缺血（多种）；系膜增生性肾小球肾炎；坐骨神经病;血管性痴呆；和视觉性癫痫。该基因的人类直系同源基因与多种疾病有关，包括 Jackson-Weiss 综合征；骨病（多发）；唇裂;血液系统癌症（多发性）；和低促性腺激素性腺功能减退症（多个）。与人 FGFR1（成纤维细胞生长因子受体 1）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables cell adhesion molecule binding activity and signaling receptor binding activity. Involved in several processes, including cellular response to histamine; neuron development; and positive regulation of cell population proliferation. Located in nucleus; perinuclear region of cytoplasm; and plasma membrane. Used to study pulmonary hypertension. Biomarker of several diseases, including ischemia (multiple); mesangial proliferative glomerulonephritis; sciatic neuropathy; vascular dementia; and visual epilepsy. Human ortholog(s) of this gene implicated in several diseases, including Jackson-Weiss syndrome; bone disease (multiple); cleft lip; hematologic Cancer (multiple); and hypogonadotropic hypogonadism (multiple). Orthologous to human FGFR1 (Fibroblast Growth Factor receptor 1). [provided by Alliance of Genome Resources, Apr 2022]

Fgfr1 基因产物(1)

mRNA	Protein	Name
NM_024146.2	NP_077060.2	fibroblast growth factor receptor 1 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables cell adhesion molecule binding	IPI IPI: 通过物理相互作用推断	19666467	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	15117958	RGD
enables protein-containing complex binding	IPI IPI: 通过物理相互作用推断	19339244	RGD
enables signaling receptor binding	IPI IPI: 通过物理相互作用推断	25485703	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in cellular response to histamine	IEP IEP: 通过表达模式推断	23497494	RGD
involved in cellular response to lipopolysaccharide	IEP IEP: 通过表达模式推断	30250515	RGD
involved in cellular response to nerve growth factor stimulus	IEP IEP: 通过表达模式推断	9011767	RGD
involved in central nervous system neuron development	IMP IMP: 通过突变表型推断	17314281	RGD
involved in female pregnancy	IEP IEP: 通过表达模式推断	7789341	RGD
involved in negative regulation of osteoblast differentiation	IMP IMP: 通过突变表型推断	18690792	RGD
involved in neuron projection development	IDA IDA: 通过直接分析推断	12791257	RGD
involved in positive regulation of cardiac muscle cell proliferation	IMP IMP: 通过突变表型推断	18275970	RGD
involved in positive regulation of fibroblast migration	IMP IMP: 通过突变表型推断	12176960	RGD
involved in positive regulation of hepatic stellate cell activation	IMP IMP: 通过突变表型推断	30250515	RGD
involved in positive regulation of mesenchymal cell proliferation	IMP IMP: 通过突变表型推断	18690792	RGD
involved in positive regulation of neuron projection development	IDA IDA: 通过直接分析推断	19952283	RGD
involved in positive regulation of neuron projection development	IMP IMP: 通过突变表型推断	22035699	RGD
involved in positive regulation of transcription by RNA polymerase II	IMP IMP: 通过突变表型推断	19229075	RGD
involved in postnatal olfactory bulb interneuron migration	IMP IMP: 通过突变表型推断	20083104	RGD
involved in regulation of cell population proliferation	IDA IDA: 通过直接分析推断	9763444	RGD
involved in regulation of stem cell proliferation	IMP IMP: 通过突变表型推断	18690792	RGD
involved in response to ischemia	IEP IEP: 通过表达模式推断	10521571	RGD
involved in response to nutrient levels	IEP IEP: 通过表达模式推断	21430024	RGD
involved in stem cell population maintenance	IMP IMP: 通过突变表型推断	19505325	RGD
involved in tangential migration from the subventricular zone to the olfactory bulb	IMP IMP: 通过突变表型推断	20083104	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in perinuclear region of cytoplasm	IDA IDA: 通过直接分析推断	10670490	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Fgfr1 蛋白结构

IgI_1_FGFR

IgI_2_FGFR

PTKc_FGFR1

0
200
400
600
822 a.a.

蛋白主名

其他名称

fibroblast growth factor receptor 1

FGF receptor-1	basic fibroblast growth factor receptor 1
proto-oncogene c-Fgr

相关产品

Approval

生物活性分子 (15)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10981	Lenvatinib	Inhibitor	99.75%	是
HY-50904	Nintedanib	Inhibitor	99.94%	是
HY-12047	Ponatinib	Inhibitor	99.67%	是
HY-18708	Erdafitinib	Inhibitor	99.66%	否
HY-13311	Infigratinib	Inhibitor	99.72%	是
HY-109099	Pemigatinib	Inhibitor	99.84%	是
HY-10208	Pazopanib	Inhibitor	99.91%	是
HY-100818	Futibatinib	Inhibitor	99.65%	否
HY-11106	Nintedanib esylate	Inhibitor	99.96%	是
HY-10981A	Lenvatinib mesylate	Inhibitor	99.86%	是
HY-N0060	Ferulic acid	Inhibitor	99.97%	是
HY-12009	Pazopanib Hydrochloride	Inhibitor	99.99%	是
HY-12297	Sulfatinib	Inhibitor	99.52%	否
HY-108766	Ponatinib hydrochloride	Inhibitor	99.55%	是
HY-13311A	Infigratinib phosphate	Inhibitor	99.74%	是

Clinical Phase

生物活性分子 (23)

目录号	产品名	作用方式	纯度	Phase
HY-101296	PD-166866	Inhibitor	99.89%	Phase 4
HY-13330	Fexagratinib	Inhibitor	99.85%	Phase 3
HY-50905	Dovitinib	Inhibitor	99.88%	Phase 3
HY-100019	Rogaratinib	Inhibitor	99.86%	Phase 3
HY-15391	Lucitanib	Inhibitor	98.94%	Phase 3
HY-10517	Orantinib	Inhibitor	99.21%	Phase 3
HY-10207	Dovitinib lactate	Inhibitor	99.75%	Phase 3
HY-B0062	Dovitinib lactate hydrate	Inhibitor	/	Phase 3
HY-101568	Roblitinib	Inhibitor	99.74%	Phase 2
HY-19981	Derazantinib	Inhibitor	99.28%	Phase 2
HY-10987A	ENMD-2076	Inhibitor	99.12%	Phase 2
HY-19957	Zoligratinib	Inhibitor	99.76%	Phase 2
HY-10987	ENMD-2076 Tartrate	Inhibitor	99.42%	Phase 2
HY-10186	TG 100801	Inhibitor	98.61%	Phase 2
HY-159642	TYRA-300	Inhibitor	/	Phase 2
HY-101466A	E7090 succinate	Inhibitor	99.17%	Phase 2
HY-10187	TG 100801 Hydrochloride	Inhibitor	/	Phase 2
HY-10339	KW-2449	Inhibitor	99.69%	Phase 1
HY-13304	LY2874455	Inhibitor	98.03%	Phase 1
HY-101768	PRN1371	Inhibitor	99.43%	Phase 1
HY-119367	ODM-203	Inhibitor	99.91%	Phase 1
HY-19983	ASP5878	Inhibitor	99.69%	Phase 1
HY-100315	XL 999	Inhibitor	99.34%	Phase 1

抗体抑制剂 (1)

目录号	产品名	作用方式	纯度	Phase
HY-P99614	Fazpilodemab	Agonist	≥99.0%	Phase 2

Pre-clinical Phase

生物活性分子 (46)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-10321	PD173074	Inhibitor	99.70%	否
HY-10407	SU 5402	Inhibitor	99.86%	否
HY-12823	BLU9931	Inhibitor	99.97%	否
HY-18602	FIIN-2	Inhibitor	99.32%	否
HY-15599	SSR128129E	Inhibitor	99.85%	否
HY-114311	FGFR1/DDR2 inhibitor 1	Inhibitor	98.26%	否
HY-148779	FGFR3-IN-5	Inhibitor	99.28%	否
HY-145231	FGFR2-IN-2	Inhibitor	98.25%	否
HY-101466	E7090	Inhibitor	99.64%	否
HY-10185	TG 100572 Hydrochloride	Inhibitor	98.96%	否
HY-100434	PD-161570	Inhibitor	99.82%	否
HY-100491	H3B-6527	Inhibitor	≥98.0%	否
HY-131908	CPL304110	Inhibitor	99.85%	否
HY-118203	SU4984	Inhibitor	99.14%	否
HY-156019	FGFR1 inhibitor-10	Inhibitor	98.92%	否
HY-16025	EOC317	Inhibitor	98.05%	否
HY-15813	FIIN-1	Inhibitor	99.11%	否
HY-18603	FIIN-3	Inhibitor	99.66%	否
HY-10517A	(Z)-Orantinib	Inhibitor	99.44%	否
HY-13737	R1530	Inhibitor	99.06%	否
HY-112345	PD-089828	Inhibitor	98.07%	否
HY-12965	S49076	Inhibitor	99.44%	否
HY-108933	JK-P3	Inhibitor	99.72%	否
HY-12047S	Ponatinib-d8	Inhibitor	99.91%	否
HY-10184	TG 100572	Inhibitor	/	否
HY-147715	FGFR3-IN-3	Inhibitor	/	否
HY-158248	FGFR4-IN-19	Inhibitor	/	否
HY-101544	ARQ 069	Inhibitor	/	否
HY-168286	FGFR-IN-16	Inhibitor	/	否
HY-152104	FGFR-IN-9	Inhibitor	/	否
HY-142921	FGFR-IN-2	Inhibitor	/	否
HY-151903S	FGFR2/3-IN-1	Inhibitor	/	否
HY-161995	FGFR1/VEGFR2-IN-2	Inhibitor	/	否
HY-143272	FGFR1 inhibitor-6	Inhibitor	/	否
HY-147713	FGFR3-IN-1	Inhibitor	/	否
HY-150652	FGFR-IN-8	Inhibitor	/	否
HY-152146	HDAC-IN-50	Inhibitor	/	否
HY-149415	Multi-kinase-IN-5	Inhibitor	/	否
HY-155028	FGFR-IN-11	Inhibitor	/	否
HY-150026	Multi-kinase-IN-2	Inhibitor	/	否
HY-139376	FGFR1 inhibitor-2	Inhibitor	/	否
HY-15599A	SSR128129E free acid	Inhibitor	/	否
HY-159503A	Segigratinib hydrochloride	Inhibitor	/	否
HY-15391A	Lucitanib dihydrochloride	Inhibitor	/	否
HY-159642G	TYRA-300 (GMP)	Inhibitor	/	否
HY-164459	AZ8010	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Fgfr1	NCBI	NCBI:2260

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4